Humacyte Files 8-K: Regulation FD & Exhibits
Ticker: HUMAW · Form: 8-K · Filed: Apr 18, 2025 · CIK: 1818382
| Field | Detail |
|---|---|
| Company | Humacyte, Inc. (HUMAW) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC filing, disclosure
TL;DR
Humacyte filed a routine 8-K, no major news.
AI Summary
Humacyte, Inc. filed an 8-K on April 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this date.
Why It Matters
This filing indicates Humacyte is meeting its regular reporting obligations with the SEC, providing transparency to investors regarding disclosures and financial statements.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting disclosures and exhibits, not indicating any new material risks or events.
Key Players & Entities
- Humacyte, Inc. (company) — Registrant
- Alpha Healthcare Acquisition Corp. (company) — Former company name
- April 17, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Humacyte, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits as of April 17, 2025.
What was Humacyte, Inc.'s former company name?
Humacyte, Inc.'s former company name was Alpha Healthcare Acquisition Corp., with a date of name change on July 16, 2020.
What is the principal executive office address for Humacyte, Inc.?
The principal executive office address for Humacyte, Inc. is 2525 East North Carolina Highway 54, Durham, NC 27713.
What is the telephone number for Humacyte, Inc.?
The telephone number for Humacyte, Inc. is (919) 313-9633.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 18, 2025 regarding Humacyte, Inc. (HUMAW).